Cammarata, E. et al. 2025. Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits. Dermatology Practical & Conceptual. 15, 3 (Jul. 2025), 5845. DOI:https://doi.org/10.5826/dpc.1503a5845.